Skip to main content
Premium Trial:

Request an Annual Quote

Lion Pens Integration Deals With Biobase, Xennex

NEW YORK, Feb. 9 (GenomeWeb News) - Lion Bioscience will integrate Biobase's network of gene-regulation data into its software products, the companies said today.

 

Separately today, Lion said it will integrate Xennex's human genes compendium GeneCards with its SRS technology.

 

According to Lion, the Biobase consolidation will enable SRS users to access Biobase's network and cellular pathway information. The Heidelberg, Germany-based bioinformatics company said it will make the Biobase network information accessible in SRS through web interfaces and specialized data viewers.

 

By associating the Biobase content with biological data offered through SRS, "scientists will be able to view networks and cellular pathways in a larger biomedical context," Lion said.

 

In the Xennex deal, Lion said that integrating SRS and GeneCards could help pharma companies improve drug research and development. Lion CEO Thure Etzold said in a statement that this deal represents "the first step" of the firms' collaboration.

 

Financial terms for either deal were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.